183 related articles for article (PubMed ID: 29913237)
1. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.
He Z; Deng W; Jiang B; Liu S; Tang M; Liu Y; Zhang J
Gene; 2018 Oct; 673():46-55. PubMed ID: 29913237
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D
Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050
[TBL] [Abstract][Full Text] [Related]
3. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
4. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S
J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971
[TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
[TBL] [Abstract][Full Text] [Related]
10. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
12. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
Li L; Huang K; Zhao H; Chen B; Ye Q; Yue J
Cell Cycle; 2020 May; 19(10):1236-1252. PubMed ID: 32275843
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression.
Studach LL; Rakotomalala L; Wang WH; Hullinger RL; Cairo S; Buendia MA; Andrisani OM
Hepatology; 2009 Aug; 50(2):414-23. PubMed ID: 19472310
[TBL] [Abstract][Full Text] [Related]
14. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
Petrelli A; Perra A; Schernhuber K; Cargnelutti M; Salvi A; Migliore C; Ghiso E; Benetti A; Barlati S; Ledda-Columbano GM; Portolani N; De Petro G; Columbano A; Giordano S
Oncogene; 2012 Oct; 31(42):4517-26. PubMed ID: 22249248
[TBL] [Abstract][Full Text] [Related]
15. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
17. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2.
Chen F; Chen C; Yang S; Gong W; Wang Y; Cianflone K; Tang J; Wang DW
PLoS One; 2012; 7(6):e39197. PubMed ID: 22761738
[TBL] [Abstract][Full Text] [Related]
18. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
19. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
Xu C; Li S; Chen T; Hu H; Ding C; Xu Z; Chen J; Liu Z; Lei Z; Zhang HT; Li C; Zhao J
Oncol Rep; 2016 Jan; 35(1):497-503. PubMed ID: 26549165
[TBL] [Abstract][Full Text] [Related]
20. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
Feng B; Wang R; Chen LB
Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]